BUZZ-Australia's Noxopharm rises on successful first dose for autoimmune disease drug** Shares of Noxopharm Ltd NOX.AX rise as much as 29.3% to A$0.097, hitting their highest level since February 14
** Stock set for best session since mid-July
** Biotech firm says first dose of autoimmune disease drug SOF-SKN found safe and tolerable
** Says, trial, aimed at checking the concentration at which the drug is tolerable, will proceed to next cohort of participants who will receive a higher dose
** Around 683,067 shares change hands, compared with 30-day avg volume of about 280,207 shares
** Session brings YTD gains to 4.3%
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.